A study conducted by researchers in the University of Toronto QUEST program, a research collaborative supported by Canadian Blood Services, looked at what can be done to reduce the number of inappropriate red blood cell transfusions in hospitals.
With an anticipated global shortage of immune globulin products, finding alternatives to IVIg can help improve availability of a drug in high demand. A recent study shows that eltrombopag, an oral medication that stimulates the production of platelets, is an effective alternative to IVIg for patients with immune thrombocytopenia who need surgery.
The Intramural Research Grant Program, one of the Centre for Innovation’s most responsive and impactful research funding programs, and the Kenneth J. Fyke Program, which supports health services and policy research, are both open for applications.
Dr. Celina Montemayor-Garcia is a researcher and transfusion medicine specialist whose main interest is understanding how genomics and bioinformatics can be used to improve care for transfusion patients. She spoke to us about advances in precision medicine and genomics, and what they could mean for the future of blood systems.
Blood plasma-derived IVIg holds promise as a treatment for Alzheimer’s disease. A new study suggests that combining IVIg with a new drug delivery technique that helps get IVIg into the brain could increase its effectiveness and help make the best use of this precious treatment.
The Centre for Blood Research’s 2020 Earl W. Davie Symposium marked the first since Dr. Davie’s passing in June. Read on to hear Kristine Ho, the Centre for Blood Research’s communication coordinator, reflect on this year’s symposium.